Mortality attributable to pandemic influenza A (H1N1) 2009 in San Luis Potosí, Mexico

Andreu Comas-García,a Christian A. García-Sepúlveda,b José J. Méndez-de Lira,c Saray Aranda-Romo,a Alba E. Hernández-Salinas,a Daniel E. Noyola,a

aMicrobiology Department, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México. bViral & Human Genomics Laboratory, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México. cServicios de Salud del Estado de San Luis Potosí, San Luis Potosí, México.

Correspondence: Daniel E. Noyola, Microbiology Department, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, Avenida Venustiano Carranza 2405, 78210 San Luis Potosí, SLP, México. E-mail: dnoyola@uaslp.mx

Accepted 27 September 2010. Published Online 3 November 2010.

Background
Acute respiratory infections are a leading cause of morbidity and mortality worldwide. Starting in 2009, pandemic influenza A(H1N1) 2009 virus has become one of the leading respiratory pathogens worldwide. However, the overall impact of this virus as a cause of mortality has not been clearly defined.

Objectives
To determine the impact of pandemic influenza A(H1N1) 2009 on mortality in a Mexican population.

Methods
We assessed the impact of pandemic influenza virus on mortality during the first and second outbreaks in San Luis Potosí, Mexico, and compared it to mortality associated with seasonal influenza and respiratory syncytial virus (RSV) during the previous winter seasons.

Results
We estimated that, on average, 8.1% of all deaths that occurred during the 2003–2009 seasons were attributable to influenza and RSV. During the first pandemic influenza A(H1N1) 2009 outbreak, there was an increase in mortality in persons 5–59 years of age, but not during the second outbreak (Fall of 2009). Overall, pandemic influenza A (H1N1) 2009 outbreaks had similar effects on mortality to those associated with seasonal influenza virus epidemics.

Conclusions
The impact of influenza A(H1N1) 2009 virus on mortality during the first year of the pandemic was similar to that observed for seasonal influenza. The establishment of real-time surveillance systems capable of integrating virological, morbidity, and mortality data may result in the timely identification of outbreaks so as to allow for the institution of appropriate control measures to reduce the impact of emerging pathogens on the population.

Keywords
Acute respiratory infections, influenza virus, mortality, pandemic influenza A (H1N1) 2009, pneumonia, respiratory syncytial virus.

Please cite this paper as: Comas-García et al. (2011) Mortality attributable to pandemic influenza A (H1N1) 2009 in San Luis Potosí, Mexico. Influenza and Other Respiratory Viruses 5(2), 76–82.
Disease Control and Prevention estimate that seasonal influenza viruses cause an average of 51,203 deaths per year in the United States, whereas RSV is thought to cause an average of 17,358 deaths per year.\(^2\) However, other researchers have estimated that the impact of respiratory viruses on mortality may be much higher than currently thought; for instance, Madjid et al.\(^{19}\) estimated that influenza virus ARIs were responsible for as many as 92,000 deaths per year in United States when cardiovascular events triggered by influenza were taken into account.\(^{19}\)

Mexico was the first country where widespread dissemination of pandemic influenza A(H1N1) 2009 virus was recorded.\(^{20,21}\) However, the impact of this virus as a cause of mortality in contrast to seasonal influenza has been difficult to assess because of several factors: (i) the unavailability of an adequate diagnostic assay early on during the initial phases of the outbreak, (ii) the technical difficulties of detecting the presence of the virus in hospitalized patients with late complications of the influenza infection, (iii) the restriction of virological testing to patients fulfilling the case definitions initially recommended, and (iv) the paucity of epidemiological data regarding the number of deaths associated with seasonal influenza that is available in Mexico.\(^{22}\) As of October 2002, we established a program to detect the presence of respiratory viruses associated with acute respiratory infections in the State of San Luis Potosí, Mexico. We have reviewed results from our surveillance program as well as local mortality data to assess the impact of pandemic influenza A(H1N1) 2009 virus in our region. In addition, this data was compared to that obtained by analyzing the impact of seasonal influenza and RSV epidemics over previous years. Although several methods have been used to define influenza epidemic periods, as well as to estimate excess mortality associated with this virus, no consensus exists regarding the best approach to define these variables.\(^{23,24}\) However, excess mortality estimates obtained with the use of simple rate difference methods have shown high correlation with those obtained with more complex statistical modeling methods.\(^{23}\) In addition, rate difference methods are more suitable to be used in areas of the world where virological data is limited. In this study, we have used an adaptation of the summer-baseline rate difference method that has been used by other authors to estimate excess morbidity and mortality associated with influenza epidemics.\(^{23,25,26}\)

**Materials and methods**

**Study population**

The State of San Luis Potosí is located in central Mexico and, according to the 2005 census, has a population of 2,410,414. There are four geographic regions in the state and a major city in each region. San Luis Potosí City is the largest city and capital of the state; the population for this metropolitan area was 957,753 in 2005.\(^{27}\)

**Mortality data**

To determine the number of deaths attributable to influenza and RSV, we used publicly available epidemiological data derived from death certificate databases;\(^{28}\) provisional data for 2009 was provided by the local Health Department (Servicios de Salud en el Estado de San Luis Potosí). These databases register the cause of death according to the International Classification of Diseases, 10th revision (ICD-10) codes. All registered deaths that occurred in the State of San Luis Potosí for which the date of death was reported were included in the analysis. We included all deaths caused by respiratory (ICD-10 codes J00-J99) and cardiovascular (ICD-10 codes I00-I99) causes as reported by Thompson et al.\(^{2}\) In addition, the contribution of influenza and RSV to all-cause mortality (all ICD-10 codes) was also estimated.

**Seasonal fluctuations of respiratory virus infections**

Local records maintained by the Virology Laboratory (Facultad de Medicina, UASLP, San Luis Potosí, Mexico) were reviewed to determine the weekly number of influenza and RSV detections in our region. Viral surveillance data is obtained with the use of immunofluorescence and molecular detection assays for influenza and RSV in samples obtained from ambulatory and hospitalized subjects with ARI. The weekly number of RSV- and influenza-positive cases was used to generate graphs depicting the seasonal fluctuations for these two viruses.

**Mortality attributable to each virus**

Based on the previously mentioned graphs of seasonal RSV and influenza infection fluctuations, we analyzed data for each respiratory season to define weeks with influenza and RSV activity; all weeks not included in these activity periods were considered as baseline and used to determine the number of excess cases attributable to each respiratory virus. A respiratory season included all weeks starting on epidemiological week 27 of a given year through epidemiological week 26 of the following year. The periods (weeks) of activity for each virus (and each season) were determined using the following algorithm: initially, we included all weeks in which the viruses were detected at least once, these weeks had to be flanked by at least three consecutive weeks in which no detection of that virus was recorded. Those weeks in which both viral agents were detected were assigned to the predominantly circulating (based on the percentage of the yearly detections of each virus). Finally, distinct RSV and influenza periods were defined based on the number of consecutive weeks in which each virus was
prevalent so as to include only one epidemic period for each virus per year. We analyzed the weekly number of cardiovascular and respiratory deaths, and deaths because of all causes during the epidemic periods of each virus; the average weekly number of cases during the corresponding baseline period was subtracted to determine the number of excess deaths that occurred during each influenza and RSV season (from here on referred to as influenza and RSV-attributable deaths). To assess overall and age-specific rates, we used the estimated population of the State of San Luis Potosí in 2005 as mentioned previously. 27

Seasonal and pandemic influenza periods
We analyzed data for the period spanning between 2003–2008 to determine the impact of seasonal influenza on morbidity and mortality. To assess the impact of pandemic A(H1N1) 2009 influenza virus, we analyzed data for two periods: the 2008–2009 influenza epidemic, which included the initial outbreak of the virus29 as well as the second outbreak of pandemic A(H1N1) 2009 registered in our city during the Fall of 2009. The impact of RSV epidemics was estimated for six winter seasons encompassed between 2003 and 2009.

Statistical analysis
The proportion of RSV and influenza-attributable deaths throughout the study years were compared using the chi-square for trend test. The effect of pandemic influenza on mortality was assessed by comparing attributable mortality rates during the first and second pandemic outbreaks with the average influenza attributable mortality rate observed during the five previous winter seasons using the chi-square test. A P value <0.05 was considered as significant. Statistical analysis was performed with the use of Epi Info 3.4.3 (Centers for Disease Control and Prevention, Atlanta, Georgia, USA).

Results
During the six winter seasons for which complete data was available (2003–2009), there were 68 583 deaths (mean 11 430.5 deaths/year; rate 474.2/100 000 persons) recorded in the State of San Luis Potosí. Of the total number of deaths, 16 310 (23.78%) were caused by cardiovascular and 6364 (9.28%) by respiratory disorders. RSV was detected in 708 and influenza virus in 192 samples tested at our Virology Laboratory during the same study period. The weekly numbers of influenza and RSV detections, as well as the seasonal mortality fluctuations, are shown in Figure 1.

The numbers of cardiovascular and respiratory deaths attributable to each virus during the 2003–2009 winter seasons are shown in Table 1. There was a trend toward decreasing numbers of cardiovascular and respiratory deaths attributable to influenza throughout the study period. Whereas cardiovascular and respiratory deaths attributable to influenza during the 2003–2004 season were

| Year | RSV | Influenza | Cardiovascular | Respiratory |
|------|-----|-----------|----------------|-------------|
| 2003 | 8   | 1         | 24             | 32          |
| 2004 | 16  | 2         | 40             | 40          |
| 2005 | 24  | 3         | 60             | 60          |
| 2006 | 32  | 4         | 80             | 80          |
| 2007 | 40  | 5         | 100            | 100         |
| 2008 | 48  | 6         | 120            | 120         |
| 2009 | 53  | 7         | 140            | 140         |

Figure 1. Seasonal fluctuations in the weekly number of all-cause deaths (no. of cases × 2), cardiovascular deaths, respiratory deaths, influenza detections, and RSV detections in San Luis Potosí, Mexico (2003–2009).
around 10–64% of all deaths, during the 2008–2009 season this percentage decreased to only 5–49% (Table 2; P<0.001; chi-square for trend). On the other hand, there was no change in the proportion of deaths attributable to RSV (8–7% for the 2003–2004 season, compared to 8% for the 2008–2009 season; P = 0.48; chi-square for trend). Mortality associated with RSV tended to be higher in most years, except the 2003–2004 and the 2007–2008 seasons.

The average estimated mortality rates for influenza and RSV infections according to age during the 2003–2008 seasons are shown in Table 3. As expected, the age group with highest mortality rates was that of adults ≥60 years.

When we analyzed the impact of pandemic influenza A(H1N1) 2009 virus epidemics (including the first outbreak and the Fall of 2009 outbreak), there was no increase in overall mortality compared to previous winter seasons. However, significant differences were observed in different age groups, as shown in Table 4: while no significant increases in mortality was registered for children <5 years or adults ≥60 years of age, there was a significant increase in cardiovascular- and respiratory-associated deaths for adults 20–59 years of age during both pandemic influenza A(H1N1) 2009 outbreaks (P < 0.001); a significant increase in all-cause mortality was registered during the first outbreak in this age group, but no increase in all-cause mortality was evident during the second outbreak of pandemic influenza A(H1N1) 2009 virus. For the 5–19 years age group, there was a significant increase in all-cause mortality during the initial pandemic influenza A(H1N1) 2009 outbreak, whereas no significant differences in mortality rates compared to previous seasons was registered during the Fall of 2009 outbreak.

Table 1. Number of cardiovascular, respiratory, and all-cause deaths associated with influenza and RSV epidemics in San Luis Potosi, Mexico (2003–2009)

| Virus | Study year | Duration (weeks) of epidemic period | Attributable cardiovascular deaths | Attributable respiratory deaths | Attributable cardiovascular and respiratory deaths | Attributable all-cause deaths |
|-------|------------|-----------------------------------|-----------------------------------|-------------------------------|-----------------------------------------------|-------------------------------|
| Influenza | 2003–2004 | 8 | 226 | 180 | 406 | 801 |
| | 2004–2005 | 12 | 60 | 73 | 133 | 153 |
| | 2005–2006 | 7 | 72 | 56 | 128 | 205 |
| | 2006–2007 | 8 | 107 | 72 | 179 | 343 |
| | 2007–2008 | 11 | 209 | 103 | 312 | 591 |
| | 2008–2009* | 17 | 89 | 126 | 215 | 475 |
| RSV | 2003–2004 | 14 | 197 | 135 | 332 | 497 |
| | 2004–2005 | 24 | 103 | 108 | 211 | 345 |
| | 2005–2006 | 17 | 277 | 150 | 427 | 667 |
| | 2006–2007 | 14 | 252 | 149 | 401 | 673 |
| | 2007–2008 | 18 | 27 | 37 | 64 | 282 |
| | 2008–2009 | 20 | 193 | 121 | 314 | 528 |

*The 2008–2009 season includes the initial pandemic influenza A(H1N1) 2009 outbreak.

Table 2. Proportion of cardiovascular, respiratory, and all-cause associated deaths attributable to influenza and RSV in San Luis Potosi, Mexico (2003–2009)

| Year | Total cardiovascular and respiratory deaths | Influenza-attributable cardiovascular and respiratory deaths (%) | RSV-attributable cardiovascular and respiratory deaths (%) |
|------|---------------------------------------------|---------------------------------------------------------------|--------------------------------------------------------|
| 2003–2004 | 3815 | 406 (10.64) | 332 (8.70) |
| 2004–2005 | 3567 | 133 (3.73) | 211 (5.91) |
| 2005–2006 | 3639 | 128 (3.52) | 427 (11.73) |
| 2006–2007 | 3826 | 179 (4.68) | 401 (10.48) |
| 2007–2008 | 3912 | 312 (7.97) | 64 (1.63) |
| 2008–2009* | 3915 | 215 (5.49) | 314 (8.02) |
| Total 2003–2009 | 22 674 | 1373 (6.05) | 1749 (7.71) |

| Year | Total all-cause deaths | Influenza-attributable all-cause deaths (%) | RSV-attributable all-cause deaths (%) |
|------|------------------------|---------------------------------------------|---------------------------------------|
| 2003–2004 | 11 342 | 801 (7.06) | 497 (4.38) |
| 2004–2005 | 10 898 | 153 (1.40) | 345 (3.16) |
| 2005–2006 | 11 036 | 205 (1.86) | 667 (6.04) |
| 2006–2007 | 11 619 | 343 (2.95) | 673 (5.79) |
| 2007–2008 | 11 671 | 591 (5.06) | 282 (2.42) |
| 2008–2009* | 12 017 | 475 (3.95) | 528 (4.39) |
| Total 2003–2009 | 68 583 | 2568 (3.74) | 2992 (4.36) |

*The 2008–2009 season includes the initial pandemic influenza A(H1N1) 2009 outbreak.
The total number of all-cause deaths attributed to pandemic influenza (H1N1) 2009 virus during the first outbreak and the Fall of 2009 outbreak in San Luis Potosí was 865. Although 31.6% of influenza attributable deaths occurred in young adults (20–59 years of age) during the first pandemic influenza A (H1N1) 2009 outbreak, during the Fall of 2009 epidemic only 4.9% of attributed deaths occurred in this age group. Overall, 6.2% of influenza attributable deaths occurred in persons 0–19 years of age, while 74.1% of all deaths occurred in adults ≥60 years of age.

**Discussion**

Respiratory viruses are responsible for a large proportion of medical consultations and deaths throughout the world. The impact of these pathogens is observed not only as ARIs, but also as exacerbations and decompensations of chronic underlying disorders, particularly cardiovascular and respiratory diseases.\(^{2,15,19}\) It is important to estimate the burden of disease for these infectious agents to assess the impact of emerging viruses, such as pandemic influenza A(H1N1) 2009 virus, as well as of the utility of preventive programs, such as vaccination campaigns.

In this study, we have estimated the impact of influenza and RSV in a Mexican population prior to and after the emergence of the pandemic influenza A(H1N1) 2009 virus. Overall, pandemic influenza A (H1N1) 2009 virus was not associated with an increase in all-cause mortality compared to previous influenza seasons. Results of an integral assessment of the first pandemic influenza wave in Réunion Island also did not find a significant increase in all-cause mortality.\(^{30}\) However, we found a significant increase in mortality during the initial pandemic outbreak for persons 5–59 years of age; this was also accompanied by a significant increase in hospital admissions and intensive care unit admissions in young adults.\(^{29}\) Similar results have been reported recently from an analysis of the impact of pandemic influenza (H1N1) 2009 virus in the United States:\(^{29}\) while the overall number of deaths attributed to this virus was within the range registered for seasonal influenza viruses over previous years, there was a significant impact on estimated years of life lost because of the younger age group of deceased patients. An important observation in our study is that during the second pandemic influenza A (H1N1) 2009 outbreak in our region (which occurred during the Fall of 2009), we did not observe an increase in all-cause deaths for any age group compared to previous seasonal influenza epidemics.

Although young adults were affected more seriously by pandemic influenza A (H1N1) 2009 virus than by seasonal influenza viruses, the greatest impact in attributable mortality was observed in older adults. These results contrast

**Table 3.** Estimated average annual influenza and RSV-associated mortality rates per 100 000 person-years in San Luis Potosí, Mexico (2003–2008)

| Virus | Age group (years) | Cardiovascular and respiratory death rate | All-cause death rate |
|-------|------------------|------------------------------------------|---------------------|
| Influenza | 0–4 | 5.3 | 14.22 |
| | 5–19 | 0.6 | 0.6 |
| | 20–59 | 2.1 | 3.81 |
| | ≥60 | 92.5 | 154.71 |
| | Total | 9.88 | 17.59 |
| RSV | 0–4 | 6.8 | 15.9 |
| | 5–19 | 0 | 0 |
| | 20–59 | 2.3 | 3.97 |
| | ≥60 | 108.26 | 183.55 |
| | Total | 11.66 | 20.46 |

**Table 4.** Estimated influenza-associated deaths during the 2003–2008 influenza seasons, 2008–2009 season (first pandemic outbreak), and the Fall of 2009 pandemic influenza outbreak

| Age group (years) | Cardiovascular and respiratory death rate* | All-cause death rate* |
|------------------|------------------------------------------|---------------------|
|                  | 2003–2008 seasons | 2008–2009 season | Fall 2009 | 2003–2008 season | 2008–2009 season | Fall 2009 |
| 0–4              | 5.3 | NA | 2.37 | 14.22 | 12.19 | NA |
| 5–19             | 0.6 | 0.86 | NA | 0.6 | 2.9 | NA |
| 20–59            | 1.21 | 3.76 | 5.09 | 3.81 | 13.58 | 1.7 |
| ≥60              | 92.5 | 75.91 | 90.51 | 154.71 | 122.24 | 164.72 |
| Total            | 9.88 | 8.91 | 10.84 | 17.59 | 19.71 | 16.05 |

*Rates per 100 000 population.
NA, no increase over baseline mortality recorded.
with the age distribution reported for confirmed pandemic influenza-associated deaths in our country in which most deaths have been recorded in adults 20–59 years of age. This difference could be explained by the fact that we included all-cause mortality, in addition to pneumonia-associated deaths, in our analysis; of note, testing for pandemic influenza virus infection has been restricted to subjects fulfilling a clinical case definition of suspected influenza infection and with short duration since the onset of symptoms (usually <5 days). Therefore, patients who may have presented with non-immediate complications of influenza infections, such as exacerbations of chronic underlying illnesses or cardiovascular events, were not eligible for testing. Castilla et al. have also reported that limiting the analysis of the impact of pandemic influenza to confirmed cases probably underestimates the effect of this virus in the elderly. In addition, studies carried out in diverse populations have shown that the highest case-fatality rates associated with confirmed pandemic influenza infections occurred in older adults.

Overall, the estimated mortality rates attributable to seasonal influenza that we describe for our population are similar to those reported from the United States, except for children <5 years of age; in this age group, the estimated mortality rate for Mexican children was significantly higher. This finding is consistent with the overall higher mortality rate for children under 5 years of age estimated by the Pan American Health Organization for Mexico (22/1000 live births) compared to that of the United States (8/1000 live births).

An additional finding in our study is the estimated effect of RSV on mortality for the Mexican population. No prior studies have addressed the impact of this virus in our country. Although the estimated cardiovascular and respiratory mortality rates attributable to influenza that we found are comparable to those reported for the United States population during the period of 1991–1999, RSV-attributable deaths were higher than those estimated in the United States. However, studies performed in other geographic areas have also found that the impact of RSV and influenza on mortality to be comparable; for instance, Fleming et al. estimated that the number of deaths attributable to RSV in England was almost the same as the one attributable to influenza. Our results show that, in addition to influenza virus, RSV is a major cause of mortality in Mexico in practically all age groups.

In summary, the emergence of pandemic influenza A (H1N1) 2009 was not associated with an increase in all-cause mortality compared to previous influenza seasons in San Luis Potosí, Mexico. During the initial epidemic outbreak, there was a significant increase in all-cause mortality for young persons (5–59 years of age), but no increase in mortality was evident during the second pandemic influenza A (H1N1) 2009 wave. Strengthening of regional respiratory virus surveillance, as well as continuous monitoring of morbidity and mortality data is required for timely identification of emerging viruses and institution of appropriate control measures geared toward limiting the social, economical, and sanitary impact of such pathogens.

Conflict of interest

Daniel E. Noyola is a member of the speakers’ bureau for Abbott Laboratories de México.

Acknowledgements

This work was supported by Fondo Mixto de Fomento a la Investigación Científica y Tecnológica CONACYT-Gobierno del Estado de San Luis Potosí (Grants number FMSLP-2006-C01-62722 and number FMSLP-2008-C01-86384) and the Universidad Autónoma de San Luis Potosí.

References

1. Bhat N, Wright JG, Broder KR et al. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med 2005; 353:2559–2567.
2. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179–186.
3. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory syncytial virus infection, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979; 300:530–534.
4. Klein MI, Coviello S, Bauer G et al. The impact of infection with human metapneumovirus and other respiratory viruses in young infants and children at high risk for severe pulmonary disease. J Infect Dis 2006; 193:1544–1551.
5. Noyola DE, Zuviri-González A, Castro-García JA, Ochoa-Zavala JR. Impact of respiratory syncytial virus on hospital admissions in children younger than 3 years of age. J Infect 2007; 54:180–184.
6. Iwane MK, Edwards KM, Szilagy PG et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004; 113:1759–1764.
7. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13:371–384.
8. Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333–1340.
9. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362:1733–1745.
10. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605–2615.
11. Fraser C, Donnelly CA, Cauchemez S et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324:1557–1561.
2009 A/H1N1 pandemic in the US and comparison with past influenza seasons. PLoS Curr 2010; 2:RRN1153.

13 Castilla J, Etxeberria J, Floristán Y, López-Escudero R, Guevara M. Estimating the impact of the 2009 influenza A(H1N1) pandemic on mortality in the elderly in Navarre, Spain. Euro Surveill 2010; 15:Pi:19481.

14 Azambuja MI. Connections: can the 20th century coronary heart disease epidemic reveal something about the 1918 influenza lethality? Braz J Med Biol Res 2008; 41:1–4.

15 Madjid M, Miller CC, Zarubaev VV et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007; 28:1205–1210.

16 Smeeth L, Casas JP, Hingorani AD. The role of infection in cardiovascular disease: more support but many questions remain. Eur Heart J 2007; 28:1178–1179.

17 Grau AJ, Fischer B, Barth C, Ling P, Lichy C, Buggle F. Influenza vaccination is associated with a reduced risk of stroke. Stroke 2005; 36:1501–1506.

18 Siscovick DS, Raghunathan TE, Lin D et al. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 2000; 152:674–677.

19 Madjid M, Naghevi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation 2003; 108:2730–2736.

20 Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S et al. Pneumonia and respiratory failure from swine-origin influenza A(H1N1) in Mexico. N Engl J Med 2009; 361:680–689.

21 Chowell G, Bertozzi SM, Colchero MA et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009; 361:674–679.

22 Kuri-Morales P, Galván F, Cravioto P, Zárraga-Rosas LA, Tapia-Conyer R. Mortalidad en México por influenza y neumonía (1990–2005). Salud Publica Mex 2006; 48:379–384.

23 Thompson WW, Weintraub E, Dhanikar P et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respi Viruses 2009; 3:37–49.

24 Sandoval C, Walter SD, Krueger P, Loeb MB. Comparing estimates of influenza-associated hospitalization and death among adults with congestive heart failure based on how influenza season is defined. BMC Public Health 2008; 8:59.

25 Izurieta HS, Thompson WW, Kramarz P et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000; 342:232–239.

26 O’Brien MA, Uyeki TM, Shay DK et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics 2004; 113:585–593.

27 Instituto Nacional de Estadística, Geografía e Informática. II Conteo de población y vivienda 2005. México, D.F.: Instituto Nacional de Estadística, Geografía e Informática, 2006. Available at http://www.inegi.org.mx/est/contenidos/espanol/sistemas/conteo2005/datos/24/pdf/cpv24_pob_2.pdf (Accessed 5 August 2009).

28 Sistema Nacional de Información en Salud. Available at http://www.sinais.salud.gob.mx/basesdedatos/index.html (Accessed 10 February 2010).

29 Gómez-Gómez A, Magaña-Aquino M, García-Sepúlveda C et al. Severe pneumonia associated with pandemic (H1N1) 2009 outbreak, San Luis Potosí, Mexico. Emerg Infect Dis 2010; 16:27–34.

30 D’Ortenzio E, Renault P, Jaffar-Bandjee MC et al. A review of the dynamics and severity of the pandemic A (H1N1) influenza virus in Réunion Island, 2009. Clin Microbiol Infect 2010; 16:309–316.

31 Fajardo-Dolci GE, Hernández-Torres F, Santacruz-Varela J et al. Epidemiological profile of mortality due to human influenza (H1N1) in Mexico. Salud Publica Mex 2009; 51:361–371.

32 Donaldson LJ, Rutter PD, Ellis BM et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009; 339:b5213.

33 Pebody RG, McLean E, Zhao H et al. Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. Euro Surveill 2010; 15:19571.

34 Louie JK, Acosta M, Winter K et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302:1896–1902.

35 Pan American Health Organization. Health indicators database, 2009. Available at http://www.paho.org (Accessed 24 April 2010).

36 Fleming DM, Pannell RS, Cross KW. Mortality in children from influenza and respiratory syncytial virus. J Epidemiol Community Health 2005; 59:586–590.